National Eye Institute (NEI): Uveitis trials
The registry lists 41 Uveitis studies with National Eye Institute (NEI) as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 12Phase 2 14Phase 3 2No phase 17(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)CompletedNCT02911116Phase 2Results posted
- Topical Interferon Gamma for Macular Edema Secondary to UveitisCompletedNCT01376362Phase 1/2Results posted
- Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal MethotrexateTerminatedNCT01314417Phase 1/2Results posted
- Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious UveitisCompletedNCT01195948Phase 1/2Results posted
- Efalizumab to Treat UveitisCompletedNCT00280826Phase 1Results posted
- Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated UveitisCompletedNCT00130637Phase 2Results posted
- Microbiome as a ThErapeutic Response BiomarkerWithdrawnNCT04721743
- Biomarkers in Ocular Inflammation and UveitisCompletedNCT04690829
- Uveitis/Intraocular Inflammatory Disease Biobank (iBank)CompletedNCT02656381
- Intestinal Bacteria and Ocular Inflammatory DiseaseCompletedNCT01859299
- Ustekinumab for Active Sight-Threatening UveitisWithdrawnNCT01647152Phase 1/2
- Immunogenetic Mechanisms in Behcet's DiseaseTerminatedNCT01109433
- The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon GammaCompletedNCT00943982Phase 1
- Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior UveitiCompletedNCT00876434Phase 1
- Genetics and Markers of Degenerative and Inflammatory Eye DiseasesCompletedNCT00647439
- Human Samples and Data RepositoryTerminatedNCT00539370
- Eye and Immunogenetic Features of SarcoidosisCompletedNCT00379275
- Differences in Genes and Proteins in Active and Controlled UveitisCompletedNCT00357266
- The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory DiseaseCompletedNCT00331331
- Combination Daclizumab/Denileukin Diftitox to Treat UveitisCompletedNCT00326508Phase 2
- Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort StudyCompletedNCT00116090
- Immune Indicators of UveitisCompletedNCT00089739
- Daclizumab and Sirolimus to Treat UveitisCompletedNCT00078689Phase 1
- Daclizumab to Treat Non-Infectious Sight-Threatening UveitisCompletedNCT00070759Phase 2
- Daclizumab Injections to Treat Non-Infectious Sight-Threatening UveitisCompletedNCT00043667Phase 2
- Vitamin E to Treat Uveitis-Associated Macular EdemaCompletedNCT00021645Phase 1
- The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid ArthritisStatus unknownNCT00012506Phase 3
- Effect of Pregnancy on UveitisCompletedNCT00001867
- HAT in Eye Complications of Behcet's DiseaseCompletedNCT00001865Phase 2
- Leflunomide to Treat UveitisCompletedNCT00001863Phase 2
- TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid ArthritisCompletedNCT00001862Phase 2
- Vascular Endothelial Growth Factor (VEGF) in UveitisCompletedNCT00001738
- Cyclosporin Implant to Treat UveitisCompletedNCT00001737Phase 1
- Screening for NEI Clinical StudiesCompletedNCT00001734
- The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid ArthritisCompletedNCT00001614Phase 1
- ANTI-TAC THERAPY FOR UVEITISCompletedNCT00001526Phase 1
- Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis PatientsCompletedNCT00001311Phase 2
- Tissue Studies of Human Eye DiseasesTerminatedNCT00001310
- Analysis of Eye TissueCompletedNCT00001224
- Collaborative Ocular Melanoma Study (COMS)Status unknownNCT00000124Phase 3
- Safety and Efficacy of a Heparin-Coated Intraocular Lens in UveitisStatus unknownNCT00000119Phase 2